Treatment related deaths, immunotherapy, immune-checkpoint inhibitors, immune-related adverse events
lung cancer, EGFR, T790-negative, Osimertinib, Patient-initiated clinical trial
non-small cell lung cancer, EGFR mutation, osimertinib, platinum-based chemotherapy, pemetrexed